Immunterápia a vesedaganatok kezelésében

The authors briefly highlight the results of targeted therapy and present new solutions in kidney cancer immunotherapy. The important checkpoint inhibitors (anti-CTLA-4, -PD-1 and -PD-L1/2) and their combinations, together with the combinations of targeted drugs and immunotherapy are discussed. The...

Full description

Saved in:
Bibliographic Details
Main Authors: Géczi Lajos
Nagyiványi Krisztián András
Maráz Anikó
Format: Article
Published: 2017
Series:MAGYAR ONKOLÓGIA 61 No. 2
mtmt:3274136
Online Access:http://publicatio.bibl.u-szeged.hu/12048
Description
Summary:The authors briefly highlight the results of targeted therapy and present new solutions in kidney cancer immunotherapy. The important checkpoint inhibitors (anti-CTLA-4, -PD-1 and -PD-L1/2) and their combinations, together with the combinations of targeted drugs and immunotherapy are discussed. The newest checkpoint agents, vaccination and pegylated interleukin-2 are also presented. The most promising clinical trials (CheckMate-025, AGS-003, IMA 901) and the on-going first line phase III trials are shown in metastatic clear cell renal carcinoma.
Physical Description:126-131
ISSN:0025-0244